Payment overview · 2025
General Payments
$525.57
22 reported records · 14 companies
Healthcare provider profile · identity verified
Charles Edwards Williams, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SMITHFIELD, NC · NPI 1598867475
Verified facts
What the public records show
CMS Open Payments records show Charles Edwards Williams, M.D. received $525.57 in general payments during 2025 across 22 reported records.
Novo Nordisk Inc accounted for 12.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $67.07 | 12.8% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $58.35 | 11.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.23 | 9.8% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $49.91 | 9.5% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $48.13 | 9.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $41.19 | 7.8% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$35.02 | 6.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.65 | 6.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $30.98 | 5.9% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $27.11 | 5.2% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $23.76 | 4.5% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $22.83 | 4.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.05 | 4.2% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.29 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $525.57 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $49.91 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $49.88 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Cardiac Ambulatory Monitor Normalized: hillrom cardiac ambulatory monitor |
Device | Baxter Healthcare | $48.13 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $41.19 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $41.19 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $41.19 | 2 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $35.02 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.30 | 2 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $30.98 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $27.11 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $23.76 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $22.83 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.93 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 65 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
126 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
65 | 65 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
80 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 487 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 366 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 356 | 93 |
| Losartan Potassium | Losartan Potassium | 345 | 89 |
| Amlodipine Besylate | Amlodipine Besylate | 334 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 252 | 76 |
| Alprazolam | Alprazolam | 214 | 56 |
| Gabapentin | Gabapentin | 202 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 169 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 167 | 48 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 158 | 32 |
| Omeprazole | Omeprazole | 157 | 42 |
| Allopurinol | Allopurinol | 154 | 38 |
| Simvastatin | Simvastatin | 150 | 39 |
| Meloxicam | Meloxicam | 146 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 145 | 34 |
| Pioglitazone Hcl | Pioglitazone Hcl | 139 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 131 | 40 |
| Prednisone | Prednisone | 128 | 72 |
| Famotidine | Famotidine | 127 | 35 |
| Ozempic | Semaglutide | 126 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 126 | 40 |
| Tramadol Hcl | Tramadol Hcl | 123 | 37 |
| Furosemide | Furosemide | 121 | 42 |
| Trazodone Hcl | Trazodone Hcl | 120 | 28 |
| Metformin Hcl | Metformin Hcl | 115 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 114 | 31 |
| Sertraline Hcl | Sertraline Hcl | 112 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 109 | 27 |
| Lisinopril | Lisinopril | 109 | 31 |
| Celecoxib | Celecoxib | 104 | 27 |
| Montelukast Sodium | Montelukast Sodium | 102 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 98 | 26 |
| Glimepiride | Glimepiride | 95 | 27 |
| Jardiance | Empagliflozin | 91 | 22 |
| Potassium Chloride | Potassium Chloride | 89 | 29 |
| Metformin Hcl Er | Metformin Hcl | 82 | 27 |
| Eliquis | Apixaban | 80 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 12 |
| Bupropion Xl | Bupropion Hcl | 77 | 23 |
| Mirtazapine | Mirtazapine | 77 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 71 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 70 | 21 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 65 | 65 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 17 |
| Solifenacin Succinate | Solifenacin Succinate | 63 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | suppressed |
| Ezetimibe | Ezetimibe | 51 | 12 |
| Cephalexin | Cephalexin | 50 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 50 | 25 |
| Breo Ellipta | Fluticasone/Vilanterol | 49 | suppressed |
| Naproxen | Naproxen | 49 | 15 |
| Spironolactone | Spironolactone | 48 | 13 |
| Donepezil Hcl | Donepezil Hcl | 47 | 14 |
| Azithromycin | Azithromycin | 45 | 37 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 13 |
| Atenolol | Atenolol | 43 | suppressed |
| Telmisartan | Telmisartan | 42 | 12 |
| Warfarin Sodium | Warfarin Sodium | 41 | suppressed |
| Ondansetron Odt | Ondansetron | 40 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 12 |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 37 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 24 |
| Ibandronate Sodium | Ibandronate Sodium | 35 | suppressed |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 25 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 23 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Nystatin | Nystatin | 30 | 15 |
| Propranolol Hcl | Propranolol Hcl | 30 | 13 |
| Linzess | Linaclotide | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | 12 |
| Dutasteride | Dutasteride | 27 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Carisoprodol | Carisoprodol | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 13 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Carvedilol | Carvedilol | 20 | suppressed |
| Gemtesa | Vibegron | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 18 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 13 |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 11 | 11 |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $525.57 · 22 records | Novo Nordisk Inc | ABRYSVO, COMIRNATY, ETERNA, EVENITY, Hillrom - Cardiac Ambulatory Monitor, INCEPTIV, INSPIRE, NUZYRA, OTEZLA, Ohtuvayre, Omnipod, PREVNAR 20, PROLIA, QULIPTA, REPATHA, REXULTI, UBRELVY, VRAYLAR, Veozah, Wegovy, XHANCE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error